0000000000228503

AUTHOR

S. Pastore

showing 3 related works from this author

Proceedings Of The 23Rd Paediatric Rheumatology European Society Congress: Part Two

2017

lcsh:Diseases of the musculoskeletal systemlcsh:RJ1-570lcsh:Pediatricslcsh:RC925-935Meeting Abstracts
researchProduct

21. Mainzer Allergie-Workshop

2009

03 medical and health sciencesmedicine.medical_specialty0302 clinical medicineOtorhinolaryngologybusiness.industryFamily medicinemedicineImmunology and Allergy030223 otorhinolaryngologybusiness030215 immunologyAllergo Journal
researchProduct

Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etan…

2017

The advent of biologic medications has increased considerably the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients. However, there is a need of data from the real world of clinical practice to evaluate thoroughly the efficacy and safety profile of the biologic agents currently approved.

Settore MED/38 - Pediatria Generale E Specialisticabiologic medications etanerceptjuvenile idiopathic arthritis
researchProduct